Thyroid carcinoma in nodules with Thy3 cytology: Retrospective study in a district general hospital
Main Article Content
Keywords
thyroid, thyroid cancer, FNAC, Thy3 cytology, hemithyroidectomy
Abstract
Background and Aim
Thyroid cancer is the most common malignant endocrine tumour. Fine needle aspiration cytology plays an important role in diagnosis of these tumours. The aim of the current study was to determine thyroid cancer risk for Thy3 cytology over a seven-year period from 2015 to 2021 at Royal Lancaster Infirmary, UK.
Methods
206 medical records with Thy3 cytology were retrospectively reviewed from January 2015 to December 2021. Patients were classified into two groups: Thy3a and Thy3f. Histopathology reports were compared with cytology reports in order to determine malignancy rates.
Results
18.9% of male patients and 23% of female patients had a malignant histology The average overall malignancy rate was 22.2%. More specifically, 22% of Thy3a and 22.4% of Thy3f were malignant. 22 patients eventually underwent completion thyroidectomy of which 6 patients had malignancy in the contralateral lobe.
Conclusion
Malignancy rates at our center was lower as compared to the national data rates.
Downloads
References
2. Cross P, Giles T, Johnson S, et al. Guidance on the Reporting of Thyroid Cytology Specimens. London. Royal College of Pathologists; 2016. www.rcpath.org/uploads/assets/7d693ce4-0091-4621-97f79e2a0d1034d6/g089_guidance_on_reporting_of_thyroid_cytology_specimens.pdf
3. Rcr.ac.uk. 2022. Audit of thyroid U-classification and subsequent fine needle aspiration cytology. The Royal College of Radiologists. https://www.rcr.ac.uk/audit/audit-thyroid-u-classification-and-subsequent-fine-needle-aspiration-cytology.
4. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol. 2010;118(1):17-23.
5. Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81(1):1-122.
6. 6. Aspinall S. Sixth national Audit Report. The British Association on Endocrine and Thyroid Surgeons; 2021. www.baets.org.uk/wp-content/uploads/BAETS-Sixth-Audit-Report-FINAL.pdf
7. Nair D, Kandiah S, Rourke T, Corbridge R, Nagala S. Malignancy rates and initial management of Thy3 thyroid nodules in a district general hospital: The 'Reading' experience. Endocrinol Diabetes Metab. 2021;4(3):e00243.
8. Ho AS, Sarti EE, Jain KS, et al. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid. 2014;24(5):832-839.
9. Alexander V, Rudd J, Walker D, et al. Thy 3F and 3a malignancy rate, a multisite regional retrospective case series. Ann R Coll Surg Engl. 2018;100(7):545-550.
10. Hassanain M, Wexler M. Conservative management of well-differentiated thyroid cancer. Can J Surg. 2010;53(2):109-118.
11. Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68-79
12. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma:
A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncology. 2016;2(8):1023-1029.
